SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders debating whether guidance, subscriber engagement and ad growth can offset concerns about slowing growth and the content slate. Sentiment leans bearish amid the stocks decline and traders claims of repeated post-earnings selloffs, though some see low expectations as room for a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious next chapter remarks have fueled buyout speculation, while traders are focused on the Phase 3 REGAL AML trials pending 80th-event trigger and eventual results; no acquisition or data leak is confirmed. The rebound has drawn bullish calls, but others view it as volatile, news-free trading and stress that the trial outcome remains uncertain.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly earnings and forward guidance are the dominant focus, particularly whether AI and data-center revenue can justify heavy capital spending. Traders are split between expecting a profitable report and rally and worrying about debt, spending, valuation, and an upcoming share unlock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets reported Willow quantum-computing advanceusing magic state cultivation to cut errors roughly 40-foldhas sparked interest, though traders question whether it will matter to the stock near term as the share price remains weak. Conversation also centers on the upcoming earnings report and whether the recent pullback is a buying opportunity or reflects broader tech and AI-spending concerns.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is drawing attention amid broader funding and return concerns for AI-focused neoclouds, with traders also questioning the companys execution, dilution and delayed Horizon capacity. Co-CEO Daniel Roberts comments that data-center construction has been cash-funded and customer prepayments help finance GPUs are cited by bulls, but have not eased the bearish debate or frustration that IREN is lagging peers.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being linked by traders both to strength across biotech and to the reported Silence Therapeutics acquisition, which some see as a sign of pharma interest in siRNA therapies relevant to Sareptas pipeline. Others view the move as a sector-driven bounce or short covering, and say upcoming DM1 and FSHD datanot a confirmed Sarepta-specific announcementwill be key.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas potential Monee fintech listing and launch of its Sea Cloud AI venture are fueling debate as shares sell off: some traders see a possible Monee separation and cloud investment as sources of uncertainty, while others argue the moves could unlock value and expand growth. The decline has intensified bearish technical commentary and speculation about insider selling, alongside bullish claims that the reaction is an overreaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are falling despite a third-quarter earnings and revenue beat and a new buyback authorization, as investors focus on a narrowed full-year profit outlook with its midpoint unchanged rather than an upgrade. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and capital returns, and seeing the outlook and softer vehicle sales as reasons for caution.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the detailed Phase 3 results for its personalized melanoma cancer vaccine with Merck at ESMO, following a positive topline readout. Bulls see the data as validation of its oncology platform, while skeptics warn that the sharp rally may have priced in strong results and could reverse on a sell-the-news reaction.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders watching Google Cloud and Gemini for signs of growth. The discussion is divided between optimism about AI and cloud momentum and concern that heavy AI spending, alongside recent share-price weakness, could weigh on returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ResMed Q4 2026 Earnings Call Transcript

ResMed (NYSE:RMD) reported fourth-quarter financial results on Thursday. The transcript from the company's fourth-quarter earnings call has been provided below.
Benzinga APIs provide real-time access to earningsread more...

ResMed Breaks Above 200-Day Moving Average - Bullish for RMD

In trading on Wednesday, shares of ResMed Inc. (Symbol: RMD) crossed above their 200 day moving average of $225.46, changing hands as high as $228.75 per share. ResMed Inc. shares are currently trading up about 2.7% on the day. The chart below shows the one year performance of...

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026 /PRNewswire/ --Pomerantz LLP is...

ResMed (RMD) Q4 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.

Resmed's stock falls by 7% on soft FY27 outlook

Resmed's stock falls by 7% on soft FY27 outlook...

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y 

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday's Pre-Market Session

US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.read more...

ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, as well as the provision of software solutions for residential care providers. It operates through the following segments: Sleep and Breathing Health and Residential Care Software. The Sleep and Breathing Health segment relates primarily to the sale of therapy-based equipment. The Residential Care Software segment provides software access with ongoing support and maintenance services as well as professional services such as training and consulting. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved

Equity

Neutral Sentiment

Analysts expect a negative impact on ResMed Inc. (RMD) after privately held pharmaceutical company and rival Apnimed, Inc. announced positive results from its late-stage clinical trial evaluating the efficacy of its lead candidate AD109 in treating obstructive sleep apnea.Apnimed <a target="_blank" rel="noopener noreferrer nofollow" href="https://apnimed.com/article/ad109phase3toplineresults/">said</a> on Tuesday that it plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) by early 2026 for regulatory review of AD109, a once-daily pill taken at bedtime.ResMed makes medical devices for treating sleep disorders such as sleep apnea.RBC Capital said in a note to investors on Tuesday that the successful commercialization of AD109 would likely negatively impact ResMed's addressable market as AD109 "could offer a less invasive, more user-friendly and viable alternative" to ResMed’s machines.RBC also noted that the company now has “a number of competitive threats on the horizon," including the possible return of Philips Respironics into the U.S. sleep apnea market after a recall of certain CPAP, BiPAP, and ventilator devices in 2021 because of potential health risks.RBC Capital has a ‘Sector Perform’ rating on ResMed, as per TheFly.Morgan Stanley analyst David Bailey, meanwhile, believes AD109 appears to focus on patients who are unable or refuse to tolerate CPAP, and expects only a “moderate” potential earnings impact for ResMed from Apnimed based on current data.Bailey keeps an ‘Overweight’ rating on ResMed with a $286 price target.On Stocktwits, retail sentiment around ResMed stayed within the ‘Neutral’ territory while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_20_at_2_20_51_PM_png_d714f3fa97.webp" alt="RMD's Sentiment Meter and Message Volume as of 2:20 p.m. ET on May 20, 2025 | Source: Stocktwits" width="630" height="64"><figcaption>RMD's Sentiment Meter and Message Volume as of 2:20 p.m. ET on May 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RMD">RMD stock </a>was down 2% on Tuesday at noon. However, it has risen by about 9% this year and by over 13% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-fails-to-convince-gop-holdouts-on-tax-bill/ch033eORbon">Trump Reportedly Fails To Convince GOP Holdouts On Tax Bill</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ResMed company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

RBC Capital noted that ResMed now has “a number of competitive threats on the horizon." 

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$RMD If health insurance starts covering CPAP therapy in Singapore and the Middle East, and they sell devices through private clinics in some European countries, profits could surge.

MIKI

$RMD short this pig…multiple new competitive threats from $PHG  & React; structural GLP-1 threat, competion from INSP, LIVN, NXYH…price gouging practices will backfire when customers fire them. 👎 $XLV $IWM

Feed

News

Sentiment

Earnings

Fundamentals

Info

RMD Resmed Inc.

Fundamentals

Latest RMD News